MARC Record from Library of Congress

LEADER: 02045cam a22003134a 4500
001 2008299448
003 DLC
005 20140717080537.0
008 080709s2008 dcua b 000 0 eng
010 $a 2008299448
020 $a9780309116688
020 $a0309116686
040 $aDLC$cDLC$dDLC
043 $an-us---
050 00 $aRC270.8$b.I47 2008
082 00 $a362.196/994007$222
245 00 $aImproving the quality of cancer clinical trials :$bworkshop summary /$cNational Cancer Policy Forum, Margie Patlack and Sharyl Nass, Rapporteurs.
260 $aWashington, D.C. :$bNational Academies Press,$cc2008.
300 $axii, 124 p. :$bill. (some col.) ;$c23 cm.
504 $aIncludes bibliographical references.
505 0 $aIntroduction -- New clinical trial designs. Phase 0 trials -- Adaptive trial designs -- Targeting multiple pathways with multiple drugs -- Preclinical model systems -- Molecular imaging. Current and developing methods -- Challenges of molecular imaging -- Screening for predictive markers. The challenges of clinical validation -- Bioimaging predictive markers -- Clinical translation -- Panel discussion -- Costs of clinical trials. Regulatory costs -- Patient accrual -- Global outsourcing -- Time is money -- Public-private collaborations -- Regulatory issues. Regulatory barriers to innovation -- Patient advocacy perspective -- Regulation of in vitro diagnostics -- Regulatory issues in improving cancer clinical trials -- Reports from the case study discussion groups. Adaptive trial design -- Phase 0 trials -- Imaging -- Use of proteomics/genomics to assign therapy in lung cancer -- Use of genetics/genomics to assign therapy.
530 $aAlso available on the World Wide Web.
650 0 $aCancer$xTreatment$zUnited States.
650 0 $aClinical trials.
700 1 $aPatlak, Margie.
700 1 $aNass, Sharyl J.
710 2 $aNational Cancer Policy Forum (U.S.)
710 2 $aInstitute of Medicine (U.S.)
856 41 $3Table of contents only$uhttp://www.loc.gov/catdir/toc/fy0805/2008299448.html